Darbepoietin alfa

USA darbepoietin alfa hematopoiesis Aranesp Nespro Recombinant analogue of human EPO with five amino acid substitutions (30 L-Asn, 32 L-Thr, 87 L-Val, 88 L-Asn, 90 L-Thr) giving five N-linked C/H chains, a MW of 38 kDa and a 52% C/H content expressed in CHO cells Hematopoiesis... 

D09C3 (anticancer antibody) 1177 Daclizumab 21, 456, 1086 Dalteparin sodium 457 Danau pkxipis 1047 Darbepoietin 16 Darbepoietin alfa 472 DARWINIZER 1779 Dash 84... 

Lerner et al. [91] also studied the pharmacokinetics of darbepoietin alfa in pedisatric patients with chronic kidney disease (CKD). Twelve patients 3-16 years of age with CKD were randomized and received a single 0.5pg/kg dose of darbepoietin alfa administered i.v. or s.c. After a 14- to 16- day washout period, patients received an identical dose of darbepoietin alfa by the alternate route. After i.v. administration, the mean clearance of darbepoietin alfa was 2.3mL/h/kg with a mean terminal half-life of 22.1 h. After s.c. administration, absorption was rate limiting, with a mean terminal half-life of 42.8h and a mean bioavailability of 54%. Comparison of these results with those from a previous study of darbepoietin alfa in adult patients [89] indicated that the disposition of darbepoietin alfa administered i.v. or s.c. is similar in adult and pediatric patients, although absorption may be slightly more rapid in pediatric patients after s.c. dosing. 

---